Amgen Inc. $AMGN Shares Acquired by Farther Finance Advisors LLC

Key Points

• Farther Finance Advisors increased its Amgen stake by 32.9% in the third quarter, bringing its holdings to 46,131 shares valued at approximately $18.0 million. Institutional investors collectively own 76.5% of Amgen’s stock.
• Analyst sentiment remains mixed, with a consensus “Hold” rating and an average price target of $388.29, below Amgen’s recent trading price near $407. The stock was recently down 1.4% and has traded between $288.00 and $447.03 over the past year.
• Amgen exceeded quarterly expectations, reporting $6.29 in EPS and $10.05 billion in revenue, up 9.5% year over year. The company also pays a quarterly dividend of $2.52, equivalent to a 2.5% annual yield.

Farther Finance Advisors LLC raised its stake in Amgen Inc. (NASDAQ:AMGN - Free Report) by 32.9% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 46,131 shares of the medical research company's stock after purchasing an additional 11,420 shares during the period. Farther Finance Advisors LLC's holdings in Amgen were worth $17,979,000 as of its most recent SEC filing.

Several other institutional investors have also recently made changes to their positions in AMGN. Sapient Capital LLC boosted its position in shares of Amgen by 13.3% during the 3rd quarter. Sapient Capital LLC now owns 3,124 shares of the medical research company's stock worth $1,317,000 after purchasing an additional 367 shares in the last quarter. CoreCap Advisors LLC increased its position in Amgen by 2.6% in the 3rd quarter. CoreCap Advisors LLC now owns 5,905 shares of the medical research company's stock valued at $2,476,000 after buying an additional 150 shares in the last quarter. Atwood & Palmer Inc. raised its stake in Amgen by 23.5% during the 3rd quarter. Atwood & Palmer Inc. now owns 6,840 shares of the medical research company's stock worth $2,883,000 after buying an additional 1,300 shares during the period. Zevenbergen Capital Investments LLC raised its stake in Amgen by 4.7% during the 3rd quarter. Zevenbergen Capital Investments LLC now owns 10,462 shares of the medical research company's stock worth $4,410,000 after buying an additional 473 shares during the period. Finally, Aletheian Wealth Advisors LLC bought a new position in Amgen in the third quarter worth approximately $206,000. Institutional investors and hedge funds own 76.50% of the company's stock.

Analyst Ratings Changes

AMGN has been the subject of several recent research reports. Argus boosted their price objective on Amgen from $375.00 to $460.00 and gave the company a "buy" rating in a report on Wednesday, August 19th. Cantor Fitzgerald boosted their price target on shares of Amgen from $400.00 to $440.00 and gave the company a "neutral" rating in a research note on Monday. Truist Financial upped their price objective on shares of Amgen from $362.00 to $380.00 and gave the stock a "hold" rating in a report on Wednesday. Bank of America raised their price objective on shares of Amgen from $312.00 to $317.00 and gave the company an "underperform" rating in a research note on Wednesday, August 5th. Finally, Oppenheimer reissued an "outperform" rating on shares of Amgen in a research report on Wednesday, September 23rd. One investment analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, sixteen have issued a Hold rating and three have assigned a Sell rating to the company's stock. According to data from MarketBeat, the company presently has an average rating of "Hold" and a consensus price target of $388.29.

Amgen Trading Down 1.4%

NASDAQ AMGN opened at $407.44 on Friday. The company has a current ratio of 1.37, a quick ratio of 1.13 and a debt-to-equity ratio of 4.44. The business has a fifty day simple moving average of $412.35 and a 200 day simple moving average of $371.88. Amgen Inc. has a 12 month low of $288.00 and a 12 month high of $447.03. The firm has a market capitalization of $220.27 billion, a P/E ratio of 25.32, a PEG ratio of 2.98 and a beta of 0.41.

Amgen (NASDAQ:AMGN - Get Free Report) last posted its quarterly earnings data on Tuesday, August 4th. The medical research company reported $6.29 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $5.62 by $0.67. Amgen had a net margin of 22.95% and a return on equity of 124.14%. The firm had revenue of $10.05 billion for the quarter, compared to the consensus estimate of $9.43 billion. During the same period in the previous year, the firm earned $6.02 EPS. The business's revenue for the quarter was up 9.5% compared to the same quarter last year. Amgen has set its FY 2026 guidance at 22.300-23.500 EPS. On average, analysts predict that Amgen Inc. will post 22.94 EPS for the current fiscal year.

Amgen Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Friday, September 11th. Shareholders of record on Friday, August 21st were given a $2.52 dividend. This represents a $10.08 dividend on an annualized basis and a yield of 2.5%. The ex-dividend date of this dividend was Friday, August 21st. Amgen's dividend payout ratio is presently 62.65%.

Key Headlines Impacting Amgen

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Amgen is advancing a Phase 3 head-to-head trial of its monthly diabetes treatment, MariTide, against semaglutide-based therapy. A successful study could strengthen Amgen’s position in the highly competitive GLP-1 and obesity-treatment markets and provide a significant future growth opportunity. Amgen’s Monthly Diabetes Shot Takes Aim at Semaglutide in New Phase 3 Trial
• Positive Sentiment: Amgen’s recently announced Sjögren’s syndrome trial results appear to have supported investor sentiment, contributing to gains in the prior session. Further details on efficacy and regulatory plans will determine the longer-term impact. Amgen Announces Sjögren’s Trial Results
• Neutral Sentiment: Amgen participated in Arboretum LifeSciences’ $30 million Series A financing for AI-driven genetic testing. The investment may give Amgen access to molecular data useful for precision-medicine research, but it is unlikely to materially affect near-term earnings. Amgen Backs $30 Million Series A Round
• Neutral Sentiment: AMGN advanced about 2.6% in the prior session while the broader market declined, suggesting recent relative strength; however, this move may also have increased the potential for profit-taking. Amgen Advances While Market Declines
• Negative Sentiment: Morgan Stanley cut its price target to $359 from $362 and maintained an Equal Weight rating. Truist raised its target to $380 but kept a Hold rating. Both targets imply downside from Amgen’s recent price, reinforcing valuation concerns. Morgan Stanley Adjusts Price Target on Amgen

Insider Transactions at Amgen

In other Amgen news, SVP Rachna Khosla sold 1,252 shares of the stock in a transaction dated Thursday, August 13th. The shares were sold at an average price of $416.43, for a total value of $521,370.36. Following the completion of the sale, the senior vice president owned 6,404 shares in the company, valued at approximately $2,666,817.72. This trade represents a 16.35% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, SVP Nancy Grygiel sold 2,970 shares of Amgen stock in a transaction that occurred on Thursday, August 6th. The stock was sold at an average price of $402.16, for a total transaction of $1,194,415.20. Following the transaction, the senior vice president directly owned 7,340 shares in the company, valued at approximately $2,951,854.40. This represents a 28.81% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 6,222 shares of company stock valued at $2,540,926 over the last ninety days. 0.85% of the stock is currently owned by insiders.

Amgen Profile

Amgen Inc is a biotechnology company that discovers, develops, manufactures and delivers medicines for serious illnesses. Its research and commercial activities focus on areas including oncology, cardiovascular disease, inflammation, bone health, neuroscience and rare diseases. The company uses biologic research, human genetics and other advanced technologies to develop targeted therapies and supports patients through treatment and disease-management services.

Amgen's portfolio includes medicines such as Enbrel for inflammatory diseases; Prolia and Evenity for osteoporosis; Xgeva for cancer-related bone complications; Repatha for certain cardiovascular conditions; Otezla for inflammatory diseases; Aimovig for migraine prevention; Tezspire for severe asthma; and Lumakras for certain cancers.

Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.